Company swung to net profit from loss, aided by lower contract services expenses
Total hospital division visits rose 9.6% yr/yr in Q2
Result Drivers
Contract services costs - Lower contract services expenses, due to a retroactive amendment to the HaloMD agreement and a reduced CMS administrative fee, drove improved profitability
IDR process impact - Revenue declined as prior-year results benefited from early-stage improvement in the IDR process, which was not repeated in 2026
Patient volume - Total hospital division visits increased 9.6% yr/yr in Q2, contributing to operational performance
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Nutex Health Inc is $233.50, about 48.5% above its August 5 closing price of $157.26
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 6 three months ago
NUTX•
